News

Significant adverse events — such as ARIA — with lecanemab, the drug that slows Alzheimer's, is rare and manageable, ...
Women are more likely to get Alzheimer's, and the way the disease works in their body may provide key insights about how it ...
The use of nucleoside reverse transcriptase inhibitors, but not other HIV medicines, is linked to a reduced risk for ...
Lecanemab binds with high affinity to soluble amyloid-beta protofibrils. It won full FDA approval in July 2023 based on trial ...
Researchers provide a new understanding of how Alzheimer’s disease affects different tissues across the entire body. The ...